First, individuals with type 2 diabetes and persistent macroalbuminuria are highly unlikely to regress to lower categories of urinary albumin excretion and their poor prognosis should prompt consideration of the use of the newer medications (GLP1-RA, SGLT2i, and finerenone) with evidence of cardiorenal benefit [34-36] in addition to optimized conventional risk management. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.